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Prescribing placebos: an experimental examination of the role of dose, expectancies, 




Background: Recent evidence indicates that placebo effects can occur even when patients 
know that they are taking a placebo, termed the open-label placebo effect. 
Aim: To assess whether placebo dose (1 pill per day versus 4 pills per day), treatment 
expectancies, and adherence contribute to open-label placebo effects.  
Method: Healthy undergraduate participants were randomly assigned to take 1 or 4 open-
label placebo pills per day, or to a no treatment control group. Placebo-treated participants 
took a 5-day course of an open-label placebo described as enhancing physical (symptoms and 
sleep) and psychological (positive and negative emotional experience) wellbeing. 
Expectancies about placebo effectiveness and wellbeing were assessed at baseline, and 
wellbeing and adherence were assessed after the 5-day course of treatment. 
Results: Medium to large open-label placebo effects were evidenced in all wellbeing 
outcomes including sleep quality. Dose did not influence these effects. Both treatment 
expectancies and adherence were significant independent predictors of enhanced wellbeing in 
the two psychological wellbeing outcomes and the experience of physical symptoms but 
sleep quality improved independently. 
Conclusions: This the first study to demonstrate the effect of open-label placebos in 
improving wellbeing and sleep quality, and to show that open-label placebo reposes do not 
appear to be dose-dependent, but for most wellbeing outcomes are independently predicted 






Placebo effects are the beneficial or healing effects of an inert treatment which result from 
receiving the treatment, but are not caused by any active ingredient in the treatment [1]. Time 
and time again, the placebo effect has been shown to have a clinically significant impact on 
not only subjective health outcomes but also objective physiological measures for a variety of 
disease states [2,3]. The same inert sugar pill can induce the release of endogenous opioids 
for analgesia [4,5], increase cortical glucose metabolism in those with depression [6], or even 
increase the release of dopamine in the brains of patients with Parkinson’s Disease [7], 
simply by altering the treatment information and delivery context. Harnessing placebo effects 
offers the possibility of improving patient outcomes and enhancing the overall efficacy of 
active medical treatments.  
One of the primary hurdles to the clinical implementation of placebo treatments are the 
ethical issues relating to use of deception, a feature common to many placebo treatments. It is 
often considered necessary for patients to believe (and thus be deceived) that they are taking a 
pharmacologically active treatment in order to harness the placebo effect [2,8]. The use of 
deception in clinical care has the potential to cause harm to individuals if they feel their 
autonomy has not been respected, and may also weaken patients’ trust in the medical profession 
[9]. As such, the perceived need for deception when administering placebos presents a barrier 
to widespread utilisation of placebo effects in medical care.  
Recent research, however, has demonstrated that placebos can still induce clinically 
significant results without the use of deception, termed the ‘open-label placebo’. Open-label 
placebos, like all placebos, are inert treatments containing no active ingredient. The key 
difference is that these placebos are given to patients alongside the knowledge that the pill is 
an inert placebo. Strikingly, open-label placebo treatments have been shown to be efficacious 
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across a range of conditions and patients, including children with ADHD [10], chronic low 
back pain and migraine pain patients [11,12], and can also significantly improve symptoms 
and quality of life in patients with Irritable Bowel Syndrome [13]. There are also preliminary 
findings of a therapeutic effect of open-label placebos in depression [14]. These results defy 
the conventional wisdom that placebos only work when patients believe they are active 
treatments, and provide the preliminary support for an ethical implementation of the placebo 
effect in clinical practice.  
Very little is currently known about the mechanisms by which open-label placebos 
have their effect [15]. However, much more is understood about placebo effects more 
generally from research using deceptive placebo paradigms. Two primary interrelated 
mechanisms have been supported as underlying placebo effects: expectancies, and classical 
conditioning [1]. Expectancy theory proposes that anticipating a particular outcome (e.g. 
symptom relief) can lead to that outcome being realised [16]. Classical conditioning of 
placebo effects involves the repeated pairing of the treatment context (e.g., a particular pill or 
salient drink with which a tablet is always taken) with the beneficial effects on an active 
ingredient. Subsequent exposure to the treatment context alone – which previously had no 
effect – results in similar effects to that of the active ingredient [17]. This direct experience of 
treatment benefit through a classical conditioning process can also result in positive 
expectancies, which mediate many conditioned placebo effects [1,18]. Conditioned placebo 
effects can persist following disclosure that the treatment was a placebo [19], but this still 
requires deception in the initial conditioning procedure. The perception that a given treatment 
is ineffective blocks the formation conditioned placebo effects [20], suggesting that prior 
conditioning does not provide an adequate explanation for the existence of open-label 
placebo effects. Although expectancies provide a promising explanation for the effectiveness 
of open-label placebo treatments, this has not yet been assessed.  
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Another important consideration for the use of open-label placebos in clinical practice 
is the ‘dose’ that should be prescribed. Prescription medications come with clear instructions 
regarding dosage, including how and when to take the treatment, which are determined by the 
pharmacological and pharmacokinetic properties of the drug, as well as clinical characteristics 
of the patient. Placebo treatments contain no active ingredients, thus the number of pills 
prescribed and dosing regimen cannot be determined in the same way. In studies 
experimentally investigating the effectiveness of open-label placebos, patients have typically 
been prescribed four placebo pills: two pills twice per day [11,13,14]. This is in line with 
previous evidence indicating that taking more placebo pills produces larger effects [21,22].  
In contrast, simplified dosing regimens comprising fewer daily doses have been 
shown to substantially increase treatment adherence [23]. Patients who are highly adherent to 
placebo treatments in RCTs have better health outcomes, compared to less adherent patients 
[24]. Effects have been found in patients treated for heart failure, myocardial infarction, HIV, 
type 2 diabetes, and immunosuppression [25]. Good adherence to placebo treatment was 
associated with about half the mortality risk of poor adherence. Although this decreased 
mortality is commonly attributed to a “healthy adherer effect” – whereby highly adherent 
patients have better outcomes because they are also likely to engage in other beneficial health 
behaviours – enhanced placebo effects or an enhanced placebo component of active 
treatments may also contribute to these beneficial outcomes [26]. The current standard open-
label placebo dosing schedule (two placebo pills taken twice per day), and the influence of 
adherence on placebo effects, are at odds with one another. On one hand, we might expect 
that taking more placebo pills more frequently might enhance the placebo effect. On the 
other, it may be that more simple dosing regimens encourage higher adherence, and thus 
larger placebo effects.   
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One way to assess the mechanisms underlying the open-label placebo effect is to 
develop relevant experimental paradigms using non-clinical samples. Numerous studies have 
utilised non-clinical samples to investigate the ‘deceptive’ placebo effect, using diverse 
research paradigms including the alleviation of pain, itch, insomnia, nausea, and anxiety [e.g. 
26–31]. Such paradigms have allowed experimental assessment of underlying mechanisms 
contributing to the placebo effect, in a way that is more challenging to achieve in clinical 
populations. To date, experimental assessment of open-label placebo effects has been in 
patient groups only, including irritable bowel syndrome [13], major depressive disorder [14], 
and chronic low back pain [11].  
The current study explores the possibility that healthy participants also experience 
open-label placebo effects, and tests a novel paradigm in which the effect of the open-label 
placebo is described as enhancing physical and psychological wellbeing. The concept of 
wellbeing is central to health, which defined by the World Health Organisation as “a state of 
complete physical, mental, and social wellbeing” [33]. Improved biomarkers of illness 
without concurrent improvements in subjective wellbeing are unlikely to be deemed 
successful or even adequate by patients [34].  
Physical wellbeing is assessed as the experience of physical symptoms, and sleep 
quality. The experience of physical symptoms is an integral part of how people view and 
manage their health [35], and the experience of symptoms is a primary driver of seeking 
medical care [36]. Poor sleep can be a precursor to or comorbid with chronic illness, and is 
associated with outcomes such as elevated blood pressure in young adults [37], and increased 
risk of developing type 2 diabetes [38]. Psychological wellbeing comprised negative and 
positive emotional states. The experience of negative emotions – including depression, 
anxiety, and stress – can both cause and result from chronic ill health [39]. For example, the 
experience of depression and anxiety predict the development of coronary heart disease and 
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type 2 diabetes [40,41]. Stress is consistently linked with heart disease, poor wound healing, 
and impaired immune function [42,43].  In contrast, the experience of positive emotions 
(independent of distress) has been linked to improved neuroendocrine, cardiovascular, and 
inflammatory activity [44], as well as longer-term health benefits including increased 
longevity, enhanced immune function, and reduced burden of heart disease [45–48].  
As such, although the paradigm was designed to investigate open-label placebo 
effects in healthy participants, the chosen outcomes are applicable and important to health 
behaviours and health outcomes in patient populations. Improvements in symptoms, quality 
of life, and depression have also been identified in open-label placebo research with patient 
populations [13,14]. Developing experimental open-label placebo paradigms with healthy 
participants will enable further exploration of the mechanisms underlying these effects. The 
aim of the current study is to empirically test the influence of expectancies, dose, and 
adherence, on open-label placebo effects on physical and psychological wellbeing in healthy 
participants. Investigating the impact of these factors is an important step in enhancing 
understanding of the open-label placebo effect, and utilising non-deceptive placebo 
treatments in clinical practice. 
METHODS 
Participants were recruited to take part in research investigating the effectiveness of open-label 
placebo administration on wellbeing. Four wellbeing factors were assessed: positive mental 
wellbeing, negative emotional states (depression, anxiety, and stress), physical symptoms, and 
sleep quality. In all advertisements, the participant information statement, and the baseline 
study session, participants were informed that they would receive inert placebo capsules 
containing only lactose (described as ‘sugar pills’). Participants were excluded if they were 
unable to consume lactose. The research was approved by the UNSW Human Research Ethics 
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Advisory Panel C (Behavioural Sciences; file 2770), and was pre-registered with the Australia 
and New Zealand Clinical Trials Registry (ACTRN12617000253303).  
Design 
This study used a between-subjects experimental design, with participants randomly assigned 
to one of three possible treatment conditions: 1) a no treatment control condition, 2) one 
placebo pill-per-day, or 3) four placebo pills-per-day. Baseline assessments of wellbeing, 
expectancies, and demographics were carried out during an in-person study session with the 
male experimenter, who was blind to treatment condition during this assessment, and 
participants completed these questionnaires on a computer running Qualtrics software in a 
research cubicle while the experimenter was in another room. Participants in the placebo 
conditions were then given placebo capsules to take home with them to take over the next five 
days. After this, participants completed online follow-up questionnaires comprising the same 
wellbeing measures as at baseline, as well as self-reported adherence.  
Participants 
Potential participants were recruited from the undergraduate psychology participant pool at 
the University of New South Wales, and received course credit for their participation. In 
total, 92 participants were enrolled in the study, provided with information about open-label 
placebos, completed the baseline assessments, and randomised to one of the three treatment 
conditions in order of attendance according to a pre-determined schedule using the random 
number generator in Excel. The experimenter was blind to group allocation until participants 
had completed the baseline questionnaires. Group allocation was approximately equal: 30 
participants were assigned to the no treatment control condition, 31 to the 1 placebo-per-day 
condition, and 31 to the 4 placebos-per-day condition. In the no treatment control group, 27 
participants (90% retention) completed follow-up questionnaires, as did 30 participants 
(97%) in the 1 placebo-per-day condition, and 31 participants (100%) in the 4 placebos-per-
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day condition. The mean age of the sample was 19 years (SD = 3.9; range 18 to 44), and 80% 
were female.  
Materials 
Placebo Capsules 
The placebos in this study were clear plant-based gel capsules containing lactose powder. 
Participants receiving placebos were given an amber pill bottle with a white screw cap 
containing their placebo capsules (1 or 4 placebo pills to take per day) to take away with 
them. These bottles were labelled with branding specifically designed for this study by the 
first author (JEB), and included the brand name (‘Plaxibax’), description of the contents, and 
dosing instructions (see Figure 1). We chose to create a brand name and associated labelling 
for the open-label placebos because previous research indicates that an association with 
branding [49,50] can increase ‘deceptive’ placebo effects.  
Measures 
At both baseline and at follow-up, participants were asked to complete questionnaires 
assessing different aspects of psychological and physical wellbeing.  
Emotional distress: the Depression Anxiety Stress Scale 21 (DASS-21) is a 21-item 
self-report questionnaire comprising depression, anxiety, and stress subscales [48]. 
Participants respond to items (e.g. “I couldn’t seem to experience any positive feeling at all”) 
on a 4-point scale from 0 (never) to 3 (almost always). Total scores were calculated by 
summing responses to all items, ranging from 0 (very low) to 63 (extremely severe) 
emotional distress. The DASS-21 has excellent internal consistency (Cronbach’s alpha = 
.93), and demonstrates good convergent validity with other validated measures of depression 
and anxiety [52].  
Positive emotions: the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) is a 
14-item self-report questionnaire that assesses overall positive mental wellbeing [53]. 
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Responses to items (e.g. “I have been feeling good about myself”) are reported on a 5-point 
Likert scale from 1 (none of the time) to 5 (all of the time), with total scores from 14 to 70, 
and higher scores indicating more positive mental wellbeing. This scale shows little evidence 
of floor or ceiling effects in either student or general populations. The WEMWBS 
demonstrates good to excellent internal consistency (Cronbach’s alpha = .89 to .91), as well 
as good content, convergent, and discriminant validity, and high test-retest reliability [53]. 
Physical symptoms: symptoms were assessed using the Subjective Health Complaints 
inventory (SHC), a list of 29 symptoms (e.g. headache, dizziness, diarrhoea) on which 
individuals rate the severity of each symptom over the past week [54]. The scale was 
modified slightly for the current study to ask about symptoms over the past 5 days. Each 
symptom is rated on an intensity scale from 0 (not at all) to 3 (severe), and these ratings are 
summed to give a score ranging from 0 to 87. The SHC has acceptable to good internal 
consistency (Cronbach’s alpha = .75 to .82) [54], and high scores on this scale are associated 
with increased healthcare utilisation [55].   
Sleep quality: the Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire 
assessing sleep quality [56]. The scale has high validity and reliability and is the most widely 
used standardised measure of sleep quality [57]. The PSQI assesses sleep quality for the 
previous month (e.g. “during the past month, how often have you had trouble sleeping 
because you wake up in the middle of the night or early morning?”). To make the scale 
appropriate for the timeframe of the current study a modified version was used to assess sleep 
quality over the past 5 days. The scale comprises seven components – each scored from 0 to 
3 – which are summed to provide a Global PSQI score ranging from 0 (very good sleep) to 
21 (very bad sleep). Total scores of 5 or higher indicate poor sleep. The PSQI shows good 
internal consistency (Cronbach’s alpha = .80), and discriminant and convergent validity [58].  
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Expectancies: in addition to the wellbeing questionnaires, after being provided with 
information about the open-label placebo effect, participants were asked about their 
expectancies of how well an open label placebo (‘Plaxibax’) would work to enhance their 
wellbeing on a scale from 0 (not at all) to 10 (extremely well). Question wording was as 
follows: “we would like to ask about your expectations regarding the effect of taking placebo 
pills on your general wellbeing. How well do you think the placebo pills will work for you?” 
Adherence: at follow-up, participants again completed the wellbeing questionnaires, 
and placebo-treated participants were also subsequently asked about how well they had 
adhered to the placebo treatment (“Over the past 5 days you were instructed to take 1 (or 4) 
placebo pill(s) per day; how well did you follow these instructions?”) on a scale from 0 (not 
well at all) to 10 (extremely well). Participants were also asked to provide a numerical 
response to the question “approximately how many placebo pills have you missed over the 
past 5 days?” These questions were prefaced with a statement asking participants to be 
honest, noting that there would be no repercussions for non-adherence, and explaining the 
importance of accurate information for the researchers.  
Because the two placebo-treated groups were given different numbers of pills to take 
per day, the number of missed pills was not directly comparable between the two groups, and 
this variable was not used in subsequent analyses. However, there was a significant negative 
correlation between self-reported adherence and number of missed pills, r (60) = -.48. Only 
one participant reported missing more than 20% of their placebo pills (i.e. taking less than 
80% of doses). In clinical studies, treatment adherence of 80% or more is associated with 
better clinical outcomes [59,60], and this is a commonly accepted level to determine clinical 
adherence. However, this participant also rated themselves as a 9 out of 10 in following their 
treatment instructions, suggesting that they may have misinterpreted the question as asking 
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about how many pills they had taken, rather than how many they had missed. Based on these 
two adherence items, participants can be considered as adherent to their placebo pills. 
Demographics: at baseline participants were asked about their age (in years) and 
gender (male, female, or other). 
Procedure 
Study participation took place over seven days. On day 1, participants attended a 30-minute 
one-on-one face-to-face session with a researcher in which information about placebos was 
provided, and baseline questionnaires were administered. The experimenter first explained 
clearly that the placebo pills were inert, with no active ingredient, ‘like sugar pills’. This 
information was followed by four discussion points outlined by Kaptchuk and colleagues [13]. 
Briefly, these were: 1) the placebo effect is powerful and placebos have been shown in 
numerous clinical trials to generate real physiological effects, 2) your body can automatically 
respond to taking placebo pills to activate mind-body healing processes, 3) positive 
expectations can help but are not crucial, and 4) that taking the pills as prescribed is important.  
 Following the placebo information provision, participants completed a baseline 
questionnaire, and were informed of their group allocation. Participants randomised to a 
placebo condition were also given placebo pills to take home with them, and instructions about 
how to take them over the next six days. Participants in the 1 placebo-per-day condition were 
given six placebo capsules and were instructed to take one each morning. Participants in the 4 
placebos-per-day condition received 24 capsules with instructions to take two in the morning 
and two at night. On day 2, participants began their placebo treatment. On day 4 (the third day 
of treatment), participants were sent a reminder email. All participants were thanked for 
attending the baseline session, and reminded that they would receive an email with a link to 
the follow-up questionnaire on day 7. In the placebo conditions, participants were also 
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reminded to take the placebo capsules as instructed. On day 7, participants received a link to 
the online follow-up questionnaire.  
Statistical Analyses 
All analyses were carried out using SPSS v.23. First, analysis of variance (ANOVA) and chi-
square analyses were used to test for any differences across the three groups in demographic 
and wellbeing factors reported at baseline.  
Next, analysis of covariance (ANCOVA) was used to assess the influence of 
treatment condition (no treatment control, one placebo per day, four placebos per day) on 
wellbeing outcomes (depression, anxiety, and stress scores, positive mental wellbeing, 
symptom burden, and sleep quality) while controlling for the baseline scores of the outcome 
variable under consideration, as per Vickers and Altman (2001). Separate analyses were 
carried out for each outcome.  Planned orthogonal contrasts were used, in which 1) the 
control group was compared to the mean of the two placebo-treated groups to test for an 
open-label placebo effect, and 2) the 1 placebo-per-day group was compared to the 4 
placebos-per-day group to test for a dose effect.  
Finally, exploratory multiple linear regression analyses (not pre-registered) were 
conducted to examine the influence of expectancies and treatment adherence on open-label 
placebo effects. Separate analyses were carried out for each wellbeing outcome. Because 
these analyses assessed the role of adherence, only placebo-treated participants were 
included. Variables were entered in three steps. In the first step, baseline scores of the 
outcome variable as well as dose condition were entered. In the second step, expectancy 
ratings and self-reported treatment adherence were entered. The interaction term between 
baseline expectancy and self-reported adherence was entered in the third step. An alpha level 
of 0.05 was used for all tests.  
RESULTS 
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At baseline, there were no differences between the groups in gender or age (see Table 1). 
Participants also did not differ in the experience of emotional distress, positive mental 
wellbeing, symptom scores, or sleep quality. Similarly, participants did not differ by group on 
baseline expectancies for treatment effectiveness (all participants received identical 
information and completed this measure prior to randomisation).  
Paired samples t-tests were conducted to assess whether baseline and follow-up 
wellbeing scores of participants in the no-treatment control group differed significantly. 
There were no significant differences over time for emotional distress (p = .88), positive 
emotional wellbeing (p = .07), physical symptoms (p = .83), or sleep quality (p = .54).  
Open-Label Placebo Effects  
 Emotional distress: participants who had taken the open-label placebo capsules 
experienced a substantial placebo effect as evidenced by significantly lower DASS scores at 
follow-up, compared to the no treatment control participants, F(1, 84) = 13.94, p < .001, 
𝑝
2  = 
.14 (see Figure 2A and Table 2). On average, the placebo-treated participants reported DASS 
scores that were 5.56 points lower than participants in the control condition (scale range: 0 – 
63; SE = 1.49, 95%CI[-8.52, -2.60]). The emotional distress scores of the 1 placebo-per-day 
and 4 placebos-per-day groups were not significantly different from one another, F(1, 84) = 
1.32, p = .25, 
𝑝
2  = .02.  
 Positive mental wellbeing: there was evidence of an open label placebo effect, with 
placebo-treated participants reporting enhanced positive mental wellbeing compared to those 
in the no treatment control condition, F(1, 84) = 10.28, p = .002, 
𝑝
2  = .11 (see Figure 2B and 
Table 2). Participants in who took the open-label placebo treatment had WEMWBS scores 
that were, on average, 5.84 points higher than participants in the control condition (scale 
range: 14 – 70; SE = 1.82, 95%CI[2.22, 9.46]). The positive mental wellbeing scores of the 1 
 14 
placebo-per-day and 4 placebos-per-day groups did not differ significantly, F(1, 84) = 2.28, p 
= .14, 
𝑝
2  = .03.  
 Physical symptoms: the planned contrast between the control group and the placebo 
treated groups revealed a significant placebo effect on symptoms, F(1, 83) = 4.73, p = .032, 

𝑝
2  = .05 (see Figure 2C and Table 2). Placebo-treated participants reported symptoms scores 
that were, on average, 5.95 points lower than those in the no treatment control group (scale 
range: 0 – 87; SE = 2.73, 95%CI[-11.39, -0.51]). The 1 placebo-per-day and 4 placebos-per-
day groups did not differ in their physical symptoms, F(1, 83) = 1.95 p = .90, 
𝑝
2  < .001.  
 Sleep quality: overall, there was an open-label placebo effect on sleep quality when 
comparing the control and placebo treated participants, F(1, 83) = 13.95, p < .001, 
𝑝
2  = .14 
(see Figure 2D and Table 2). Those in the open-label placebo group had PSQI scores that 
were, on average, 1.57 points lower (indicating improved sleep quality) than participants in 
the control condition (scale range: 0 to 21; SE = 0.42, 95%CI[-2.40, -0.73]). The 1 placebo-
per-day and 4 placebos-per-day groups did not differ significantly in their reported sleep 
quality, F(1, 83) = 1.82, p = .18, 
𝑝
2  = .02.   
Predictors of Open-Label Placebo Effects 
Next, we tested whether treatment expectancies and self-reported adherence were predictive 
of open-label placebo effects in each of the four wellbeing outcomes. These analyses were 
carried out using data from only placebo-treated participants who completed the follow-up 
questionnaire.  
 Expectancies and adherence: expectancy ratings at baseline did not differ between the 
1 placebo-per-day (M = 5.13, SE = 0.44) and 4 placebos-per-day (M = 5.00, SE = 0.40) 
groups, t(60) = 0.22, p = .83. Self-rated adherence to the placebo treatment was significantly 
higher in the 1 placebo-per-day condition (M = 9.27, SE = 0.22) than the 4 placebos-per-day 
condition (M = 8.23, SE = 0.31), t(58) = 2.75, p = .008. A Pearson’s correlation between 
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baseline treatment expectancies and subsequent treatment adherence was not significant, r (n 
= 60) = -.16, p = .21. Because groups differed in self-reported adherence, number of placebos 
per day (1 or 4) was included as a control variable in the regression analyses. 
Emotional distress: the combination of group and baseline DASS scores accounted 
for a significant proportion of variance in depression, anxiety, and stress scores at follow-up, 
F(2, 57) = 13.26, p < .001, R2adj = .29. The addition of baseline expectancies and self-reported 
adherence added significantly to explained variance, F(2, 55) = 9.23, p < .001, R2change = .17. 
Both expectancies and adherence were significant predictors of DASS scores at follow-up, 
with higher expectancies and higher adherence both predicting lower scores. The addition of 
the expectancy by adherence interaction term did not add to explained variance, F(1, 54) = 
0.42, p = .52, R2change = .004 (see Table 3).    
 Positive mental wellbeing: the control variables accounted for a significant proportion 
of variance in WEBWMS scores at follow-up, F(2, 57) = 22.88, p < .001, R2adj = .43. The 
addition of expectancies and adherence in the second step of the model explained an 
additional 12% of the variance in post-treatment positive mental wellbeing, F(2, 55) = 7.76, p 
= .001. Higher expectancies and adherence were significant predictors of higher WEBWMS 
scores. Adding the expectancy by adherence interaction did not explain any additional 
variance in the outcome measure, F(1, 54) = 0.007, p = .93, R2change = .000 (see Table 3).  
 Physical symptoms: together, baseline symptoms and dose were significant predictors 
of symptoms at follow-up, F(2, 57) = 16.94, p < .001, R2adj = .35. Adding expectancies and 
adherence accounted for an additional 7.4% of the variance in physical symptoms, F(2, 55) = 
3.65, p = .032. When examining individual predictors, both higher expectancies and 
adherence predicted fewer symptoms post-treatment. The expectancy by adherence 
interaction did not explain additional variance, F(1, 54) = 2.30, p = .14, R2change = .02 (see 
Table 3).  
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 Sleep quality: the control variables, again, were significant predictors of post-
treatment sleep quality, F(2, 57) = 32.78, R2adj = .52. However, in the case of sleep quality, 
the addition of expectancies and adherence in the second step of the model did not explain 
any additional variance in sleep outcomes, F(2, 55) = 0.53, p = .59, R2change = .01. Neither 
expectancies nor adherence predicted post-treatment sleep-quality. Similarly, adding the 
expectancy by adherence interaction to the model did not predict additional variance in sleep 
quality, F(1, 54) = 1.81, p = .18, R2change = .02 (see Table 3).  
 Given that participants who took the open-label placebo reported better sleep quality 
than those in the no treatment control condition, this result was surprising. To test whether 
improvements in the other wellbeing outcomes might have contributed to improved sleep 
quality independent of expectancies or adherence, change scores were calculated (post – pre) 
for DASS, WEMWBS, and SHC scales. Three separate regression models were run, to test 
whether changes in these other outcomes predicted sleep quality at follow-up. Again, 
baseline sleep quality and dose were entered as control variables, and then change scores 
were entered in the second step of each model. Changes in depression, anxiety, and stress 
scores (p = .98), positive mental wellbeing scores (p = .30), and symptoms scores (p = .67) 
did not predict improved sleep quality following placebo treatment.  
 Control condition: additional exploratory regression analyses were conducted with 
only participants allocated to the no treatment control condition. These analyses examined the 
influence of baseline expectancies on each of the wellbeing outcomes, with baseline scores of 
the respective outcome variables entered as control variables in the first step of the model, 
and expectancies entered in the second step. This analytic strategy allowed us to assess the 
possibility that holding positive expectancies at baseline might have been predictive of 
enhanced wellbeing outcomes even in the absence of placebo treatment. Conversely, 
participants with positive baseline expectancies might have been disappointed at being 
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randomised to the no treatment control condition, and subsequently experienced poorer 
wellbeing outcomes. The results of these analyses indicate that baseline expectancies in the 
control group were not significant predictors of subsequent wellbeing outcomes, in either 
direction (see Table 4).   
DISCUSSION 
This study is the first to demonstrate the efficacy of open-label placebo treatments for 
enhancing wellbeing in healthy participants, specifically in reducing the experience of 
emotional distress and physical symptoms, and enhancing positive mental wellbeing and 
sleep quality. In addition, the results provide important insights into the underlying 
mechanisms of open-label placebo effects. Expectancies prior to treatment, and adherence to 
the placebo capsules, were significant independent predictors of psychological wellbeing 
outcomes and physical symptoms. Although 1 placebo-per-day administration was associated 
with enhanced treatment adherence, no significant differences in wellbeing outcomes were 
seen between the 1 per-day and 4 per-day open-label placebo-treated participants.  
 The results with regard to expectancies are generally in line with prior research into 
‘deceptive’ placebo effects, which also identifies the belief that a treatment will be effective 
as a primary psychological mechanism underlying the effect [1,16]. Baseline expectancies 
predicted improvements in the experience of emotional distress, physical symptoms, and 
positive emotional wellbeing. Future research should explore the contributors to positive 
expectancies about open-label placebo treatments – such as personality factors and beliefs 
about traditional and complementary treatments – and what strategies might be used to 
enhance perceptions in those who are sceptical in order to facilitate optimal health outcomes. 
Recent research has shown that positive beliefs about holistic treatments and perceived 
necessity of a treatment can enhance the placebo effect of an inert cream described as being 
natural in origin [62]; similar beliefs may also contribute to open-label placebo effects. 
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Notably, expectancy ratings in the present study were not particularly high. When asked how 
well they believed the open-label placebo would work for them, the mean expectancy rating 
was 4.9 (on a scale from 0 to 10). At best, this represents a moderate belief in the placebo, 
and likely indicates a degree of uncertainty about how effective the capsules might be in 
enhancing wellbeing.   
Participants’ self-reported adherence also significantly predicted the magnitude of 
placebo effects in psychological wellbeing outcomes, and the experience of physical 
symptoms. This finding is consistent with previous research demonstrating that patients who 
were highly adherent to placebos in double-blind clinical trials had better health outcomes 
[25], and supports the proposition that this benefit may reflect – at least in part – an enhanced 
placebo effect [26]. To add to the words of former US Surgeon General C. Everett Koop, 
neither drugs – nor placebos – work in patients who don’t take them. Unlike active medical 
treatments, positive beliefs about the open-label placebo were unrelated to subsequent 
adherence [63]. Expectancies and adherence had independent effects on open-label placebo 
effects. All open-label placebos in the current study had brand name labelling. This 
association with visual information typically accompanying branded active pharmaceuticals 
may have enhanced treatment expectancies and contributed to the observed outcomes 
[50,64]. Future research could systematically examine the contribution of brand name 
labelling to open-label placebo effects.  
Taking more placebo pills each day did not enhance the open-label placebo effect. 
This finding is in contrast to research in which participants believe the placebo treatment to 
be an active drug [21,22]. More frequent engagement with pill-taking behaviour did not 
provide greater benefits. Indeed, in sleep as well as emotional distress and positive mental 
wellbeing outcomes, there were small but non-significant effects in favour of the 1 placebo-
per-day treatment, which can potentially be explained by increased adherence in this 
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condition. This finding provides evidence that the mechanisms underlying deceptive and 
open-label placebo effects differ, particularly with regard to what constitutes perceived 
treatment strength or potency. When patients believe that the treatment they are taking 
contains an active ingredient, it follows that taking more pills may be indicative of a higher 
dose of the active ingredient and thus a stronger treatment. It seems that participants in the 
current study did not conceptualise taking more pills as being indicative of a larger ‘dose’ of 
the placebo treatment. However, it may be that the prescribed doses (1 versus 4 placebos per 
day) were not sufficiently different from one another to see an effect; for example, 
participants may have viewed both treatment regimens as providing a ‘high dose’ of placebo 
treatment. Future research investigating how to enhance the perceived strength of open-label 
placebos would add to evidence-based clinical application.  
 The present study suggests  that open-label placebo administration of four pills per 
day – as has been done in previous experimental research [11,13,14] – may be unnecessary. 
In order to test whether higher doses would be associated with greater open-label placebo 
effects, we compared the effects of single vs multiple dose placebos. More does not appear to 
be better in this context, but taking the placebo pills as prescribed is important. Making 
adherence as easy as possible for patients has the potential to further enhance the efficacy of 
open-label placebo treatments, and simplified dosing regimens of one placebo pill per day 
may be preferable [23]. 
Although improvements in sleep quality showed a large open-label placebo effect in 
comparison to the no treatment control condition, this effect was unrelated to baseline 
expectancies. Further, changes in the other wellbeing outcomes were unable to account for 
these findings. These results are surprising, and we propose two possible explanations to 
account for this. First, it may be that physical symptoms, and negative and positive emotional 
experiences, are more closely aligned with lay conceptualisations of ‘wellbeing’ than sleep 
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quality. The single item general expectancy measure may have tapped into beliefs about these 
outcomes preferentially. Future research would benefit from using more specific outcome 
expectancy assessments. Second, although overall changes in the other wellbeing factors did 
not predict the magnitude of sleep quality improvements, it may be that initial positive 
experiences may have contributed to enhanced expectancies for sleep quality, or that 
improvements in psychological wellbeing directly contributed to sleep outcomes. Assessing 
expectancies during treatment may contribute to understanding of the development of open-
label placebo effects.  
Similarly, improvements in sleep quality were not associated with self-reported 
adherence to placebo treatment. Adherence to the placebo administration instructions was 
assessed only at the end of the treatment course. It may be that adherence in this context was 
more important on a day-by-day basis, i.e. that taking a placebo pill or pills during the day 
was associated with improved sleep only on that night. Indeed, previous research highlights 
the large placebo component associated with hypnotic drug treatments [65]. Assessing 
adherence more regularly throughout the treatment, rather than as a retrospective recall, 
might offer more insights into the potential contribution of adherence to open-label placebo 
effects. It is also possible that additional factors that were not assessed in the current study 
may have contributed to sleep quality outcomes. A number of possible contributors have 
been put forward by Ballou and colleagues [15], including hope, prediction processing and 
the attribution of normal variation to treatment effects (leading to actual subsequent 
improvement), cognitive reappraisal, and aspects of the clinical interaction. Future research 
would benefit from developing a broader understanding of the factors than can enhance open-
label placebo effects. 
 The current study has a number of strengths. The experimenter was blind to the 
participants’ group allocation during the baseline assessment, and the follow-up questionnaire 
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was conducted online, minimising the possibility of experimenter bias or demand 
characteristics influencing the results. In addition, measures including the WEMWBS show 
low social desirability bias [53]. This does not preclude the possibility that social desirability 
and demand characteristics could have influenced the self-reported outcomes. However, the 
use of a computer-administered questionnaire during the study session that was completed in 
the absence of the experimenter, and a follow-up questionnaire also administered online away 
from the research environment may have been helpful in addressing these potential 
limitations; evidence suggests that such methods can result in lower social desirability bias in 
responses [66].  
The minimal experimenter contact, and with a student researcher, provides evidence 
that open-label placebo effects can occur in the absence of a warm and supportive ongoing 
relationship with a medical professional [13]. Although these factors are certainly likely to 
contribute to enhanced outcomes, they do not appear to be necessary to generate open-label 
placebo effects, at least in healthy participants. In addition, participants were informed that 
they were taking part in a study of the open-label placebo effect, but they were unaware of 
the dose manipulation, strengthening these results. Finally, the study sought to assess possible 
mechanisms contributing to open-label placebo effects: expectancies, dose-response, and 
adherence. The placebo treatment was administered over a 5-day course, allowing the 
assessment of adherence. To our knowledge this is the first experimental study to investigate 
possible mechanisms underlying the open-label placebo effect.  
The research is potentially limited by the use of a healthy student sample. However, 
the paradigm was designed for use in this population, allowing greater experimental control 
and assessment of underlying mechanisms. Previous research has found open-label placebo 
effects in clinical samples across a range of age groups and conditions [10,11,13,14], and 
evidence of open-label placebo effects in healthy participants in the current study adds to our 
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understanding of this phenomenon. University students commonly report high levels of 
distress and health complaints, poor sleep quality, and low levels of positive mental 
wellbeing [67–70]. At follow-up in the current study, only 59% of no treatment control 
participants were in the normal range for depression scores [71], compared to 80% of open-
label placebo-treated participants. The magnitude of these differences have potential 
implications for health outcomes; even subclinical levels of depression have been linked with 
increased risk of mortality [72]. 
 The present study may also have been limited by the use of a single-item self-report 
measure of treatment adherence, rather than using a structured multi-item questionnaire or the 
inclusion of a pill count at follow-up. However, many commonly used self-report 
questionnaires assess aspects of adherence such as choosing to stop taking medication due to 
adverse effects, which were less applicable for the current study [e.g. 72]. Promisingly, 
single-item self-rated adherence measures like the one used in this study have been shown to 
provide estimates of adherence similar to unannounced pill counts [74], and self-reported 
adherence is a good predictor of clinical health outcomes [75]. In addition, instructions to 
participants in conjunction with the online follow-up may have encouraged generally honest 
responding and reduced possible social desirability bias.  
Finally, providing all participants with open-label placebo information prior to 
randomisation may have resulted in disappointment in those allocated to the no treatment 
control condition, which could have caused a nocebo-like effect [see 76 for a review] 
whereby group differences seen in the current study were due to control participants 
experiencing worse outcomes (rather than improvement in placebo-treated participants). 
However, the wellbeing scores of control group participants did not significantly diminish 
over time, and positive expectancies in this group did not predict subsequent negative 
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outcomes. Future research would be strengthened by providing information about open-label 
placebos only to placebo-treated participants.  
 The current study, to our knowledge, is the first to explore the mechanisms underlying 
open-label placebo effects. Results indicate that both expectancies and adherence contribute 
to enhanced wellbeing outcomes. In contrast, taking more pills per day did not offer 
additional benefits. In previous research with clinical populations, patients are typically given 
two placebo pills to take twice per day [13]. The results of the current study indicate that this 
approach may not be optimally harnessing adherence-driven mechanisms of the open-label 
placebo effect, and that simplified dosing regimens and other adherence-enhancing strategies 
might yield even larger effects than have been evidenced to date. Understanding the factors 
that contribute to open-label placebo effects will allow for optimal application in clinical 
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Gender (% female) 80% 77% 84% 0.42 .81 
Age 18.9 (2.00) 20.0 (4.86) 20.5 (3.87) 1.26 .29 
Emotional distress (DASS) 12.73 (9.04) 16.09 (12.28) 14.97 (8.41) 0.88 .42 
Positive mental wellbeing (WEMWBS) 47.70 (8.95) 47.71 (10.76) 46.90 (9.31) 0.07 .93 
Physical symptoms (SHC) 16.43 (8.88) 20.68 (12.31) 19.58 (10.09) 1.33 .27 
Sleep quality (PSQI) 7.20 (2.54) 7.03 (2.95) 7.25 (2.72) 0.06 .95 





Table 2. Mean (SE; 95%CI) between-group post-treatment scores for each outcome variable, adjusted for the corresponding baseline scores.   
 
 Control 
M (SE; 95%CI) 
1 placebo-per-day  
M (SE; 95%CI) 
4 placebos-per-day  
M (SE; 95%CI) 
Emotional distress (DASS) 13.47 (1.24; 11.01 to 15.93) 6.97 (1.17; 4.64 to 9.30) 8.48 (1.15; 6.57 to 11.13) 
Positive mental wellbeing (WEMWBS) 45.07 (1.52; 42.05 to 48.09) 52.44 (1.44; 49.48 to 55.30) 49.39 (1.42; 46.57 to 52.20) 
Physical symptoms (SHC) 16.93 (2.28; 12.39 to 21.46) 10.80 (2.12; 6.59 to 15.01) 11.16 (2.07; 7.03 to 15.28) 
Sleep quality (PSQI) 7.09 (0.35; 6.39 to 7.79) 5.22 (0.33; 4.56 to 5.87) 5.83 (0.32; 5.19 to 6.47) 
 32 
Table 3. Standardized beta, t-, and p-values from the full regression model (for placebo-
treated participants only) for each outcome variable.  
  t p-value 
Depression, Anxiety, and Stress    
Baseline DASS 0.59 6.04 <.001 
Dose 0.02 0.23 .86 
Expectancy -0.36 -3.41 .001 
Adherence -0.36 -3.24 .002 
Expectancy x Adherence 0.07 0.65 .52 
Positive Mental Wellbeing    
Baseline WEMWBS  0.63 7.02 <.001 
Dose -0.06 -0.67 .51 
Expectancy 0.31 3.18 .002 
Adherence 0.25 2.46 .017 
Expectancy x Adherence -0.01 -0.08 .93 
Symptoms Score    
Baseline SHC 0.67 6.47 <.001 
Dose -0.04 -0.42 .68 
Expectancy -0.29 -2.60 .012 
Adherence -0.27 -2.39 .020 
Expectancy x Adherence 0.17 1.52 .14 
Sleep Quality    
Baseline PSQI 0.70 7.72 <.001 
Dose 0.14 1.49 .14 
Expectancy 0.01 0.13 .90 
Adherence 0.13 1.25 .22 








Table 4. Standardized beta, t-, and p-values from the control group only regression model for 
each outcome variable.  
  t p-value 
Depression, Anxiety, and Stress    
Baseline DASS 0.82 6.94 <.001 
Expectancy 0.05 0.45 .66 
Positive Mental Wellbeing    
Baseline WEMWBS  0.84 7.01 <.001 
Expectancy -0.13 -1.10 .28 
Symptoms Score    
Baseline SHC 0.22 1.06 .30 
Expectancy -0.10 -0.47 .65 
Sleep Quality    
Baseline PSQI 0.91 9.12 <.001 







Figure 1. Labels for the 1 per-day (left) and 4 per-day (right) open-label placebo conditions. 
 
Prescription:  Placibax™  Placebo  Capsules  
Directions:    Take 1 capsule daily with water 
                   
Qty : 6 
Rx : 7522-229-001 
Oral Placebo Capsules 
            Clinical Trial | Researcher: Jason El Brihi | Contact: jasonelbrihi@gmail.com 
 
Prescription:  Placibax™   Placebo   Capsules  
Directions:    Take 4 capsules daily with water 
                  2 in morning and  2  before  bed 
Qty : 24 
Rx : 7522-229-001 
Oral Placebo Capsules 
            Clinical Trial | Researcher: Jason El Brihi | Contact: jasonelbrihi@gmail.com 
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Figure 2.  Bar graphs showing baseline-adjusted mean (SE) scores for no treatment control, 1 placebo-per-day (ppd), and 4 placebos-per-day 
(ppd) conditions across wellbeing outcomes of A) emotional distress, B) positive mental wellbeing, C) physical symptoms, and D) sleep quality. 
*** p < .001; ** p < .01; * p < .05 
